Lilly Offers Underwhelming 2016 Forecast; Merck On Deals

Lilly Offers Underwhelming 2016 Forecast; Merck On DealsLilly Offers Underwhelming 2016 Forecast; Merck’s CEO Says The Company Is ‘Raring To Go’ On Deals

Also, Valeant names a new CEO while 21st Century Oncology withdrew its long-delayed public offering.

The Associated Press: Drugmaker Lilly’s 2016 Forecast Misses Street Expectations Eli Lilly has dropped a lower-than-expected 2016 forecast on Wall Street after wrapping up a year in which its stock soared above the broader market. … Lilly, also known for the erectile dysfunction drug Cialis and its portfolio of cancer treatments, has been recovering from the loss of patents protecting key products like the antidepressant Cymbalta from cheaper generic drugs. (1/5)

The Associated Press: Merck CEO: Eager For Deals, Strong Prospects For New Drugs Merck’s chief executive says the drugmaker is “raring to go” on deals this year, particularly for small and midsize acquisitions of companies or their experimental drugs. CEO Kenneth Frazier, speaking Tuesday at a Goldman Sachs conference of CEOs of health care companies in Boston, also said he expects more approvals and growing sales from new cancer drug Keytruda. (1/5)

The Wall Street Journal: 21st Century Oncology Withdraws IPO 21st Century Oncology Holdings Inc., the cancer-care giant that was recently embroiled in a Medicare billing investigation, on Tuesday withdrew its long-delayed initial public offering. In a regulatory filing, 21st Century Oncology said it had decided not to pursue the offering at this time. The company didn’t provide further detail. (Dulaney and Carreyrou, 1/5)

Bloomberg: Valeant To Name New CEO As Pearson Hospitalized, WSJ Says Valeant shares dropped 4.8 percent to $96 in late trading after the Journal report. Through Tuesday’s close, they had fallen 12 percent since Pearson’s hospitalization was disclosed on Christmas Day. … The drugmaker announced that Pearson was taking a medical leave of absence starting on Dec. 28, and that the company would be run by a team of three executives, including General Counsel Robert Chai-Onn, Executive Vice President Ari Kellen and CFO Rosiello. Valeant board members Schiller, Robert Ingram and Mason Morfit were tapped to oversee the executives. (Armstrong, 1/5)

This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations.

Copyright 2000 © Medical & Health